Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome
Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome
复制标题
DOI：
10.1111/j.1365-2141.2006.06097.x
复制
发表时间：
2006-06-01
影响因子：
6.5
通讯作者：
Hitzler, Johann
中科院分区：
文献类型：
--
作者：
Al-Ahmari, Ali;Shah, Niketa;Hitzler, Johann
患有急性巨核母细胞白血病（AMKL）和唐氏综合征（DS）的儿童对化疗反应良好，可能是由于白血病原细胞对阿糖胞苷的敏感性增加。相比之下，剂量强化方法导致该组中不成比例的治疗相关死亡率。采用低剂量化疗方案，包括阿糖胞苷（10mg /m(2)/剂量）、视黄醇棕榈酸酯和长春新碱或标准化疗，回顾性比较AMKL和DS患儿的生存率。两组5年无事件（67 +/- 11%）和总生存率（77 +/- 10%）无显著差异。因此，进一步降低退行性痴呆患儿AMKL的治疗强度似乎是可行的。
Children with acute megakaryoblastic leukaemia (AMKL) and Down syndrome (DS) show a favourable response to chemotherapy, probably due to increased sensitivity of the leukaemic blasts to cytarabine. In contrast, dose-intensive approaches have resulted in disproportionate treatment-related mortality in this group. The survival of children with AMKL and DS was retrospectively compared following treatment with a low-dose chemotherapy protocol, consisting of cytarabine (10 mg/m(2)/dose), retinylpalmitate and vincristine or standard chemotherapy. Event-free (67 +/- 11%) and overall survival (77 +/- 10%) at 5 years were not significantly different in both groups. Further reduction of treatment intensity in AMKL of children with DS, therefore, appears feasible.